This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ephrin receptor
From Proteopedia
(Difference between revisions)
| Line 18: | Line 18: | ||
<scene name='45/450911/Cv/10'>Peptide substrate binding site</scene> ([[3fxx]]).<ref>PMID:19678838</ref> | <scene name='45/450911/Cv/10'>Peptide substrate binding site</scene> ([[3fxx]]).<ref>PMID:19678838</ref> | ||
| + | |||
| + | == 3D Structures of ephrin receptor == | ||
| + | [[Ephrin receptor 3D structures]] | ||
| + | |||
</StructureSection> | </StructureSection> | ||
== 3D Structures of ephrin receptors == | == 3D Structures of ephrin receptors == | ||
| Line 25: | Line 29: | ||
*Ephrin A1 receptor | *Ephrin A1 receptor | ||
| + | |||
**[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | **[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | ||
**[[3hil]] - hEPHR A1 SAM<br /> | **[[3hil]] - hEPHR A1 SAM<br /> | ||
| - | **[[2k1k]] - hEPHR A1 transmembrane domain – NMR<BR /> | + | **[[2k1l]], [[2k1k]] - hEPHR A1 transmembrane domain – NMR<BR /> |
| - | **[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR | + | **[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR |
| - | *Ephrin A2 receptor | + | |
| - | **[[3hpn]], [[3c8x]] - hEPHR A2 LBD | + | *Ephrin A2 receptor; domains – LBD 28-200; ectodomain 27-435; kinase 596-900 |
| - | **[[2x10]], [[3fl7]] - hEPHR A2 ectodomain | + | |
| + | **[[3hpn]], [[3c8x]] - hEPHR A2 LBD<BR /> | ||
| + | **[[2x10]], [[3fl7]] - hEPHR A2 ectodomain<BR /> | ||
**[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | **[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | ||
| - | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain | + | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain<BR /> |
*''Ephrin A2 receptor binary complex''<br /> | *''Ephrin A2 receptor binary complex''<br /> | ||
| Line 40: | Line 47: | ||
**[[3hei]], [[3czu]] - hEPHR A2 LBD + ephrin A1<BR /> | **[[3hei]], [[3czu]] - hEPHR A2 LBD + ephrin A1<BR /> | ||
**[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | **[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | ||
| + | **[[6njz]], [[6nk0]], [[6nk1]], [[6nk2]], [[6nkp]], [[6b9l]] - hEPHR A2 LBD + peptide<br /> | ||
**[[2kso]] - hEPHR A2 SAM fragment residues 945-969 + SHIP2<br /> | **[[2kso]] - hEPHR A2 SAM fragment residues 945-969 + SHIP2<br /> | ||
**[[5nz9]] - hEPHR A2 SAM fragment<br /> | **[[5nz9]] - hEPHR A2 SAM fragment<br /> | ||
**[[5i9v]], [[5i9w]], [[5njz]], [[5nk0]], [[5nk1]], [[5nk2]], [[5nk3]], [[5nk4]], [[5nk5]], [[5nk6]], [[5nk7]], [[5nk8]], [[5nk9]], [[5nka]], [[5nkb]], [[5nkc]], [[5nkd]], [[5nke]], [[5nkf]], [[5nkg]], [[5nkh]], [[5nki]] - hEPHR A2 kinase domain + inhibitor<br /> | **[[5i9v]], [[5i9w]], [[5njz]], [[5nk0]], [[5nk1]], [[5nk2]], [[5nk3]], [[5nk4]], [[5nk5]], [[5nk6]], [[5nk7]], [[5nk8]], [[5nk9]], [[5nka]], [[5nkb]], [[5nkc]], [[5nkd]], [[5nke]], [[5nkf]], [[5nkg]], [[5nkh]], [[5nki]] - hEPHR A2 kinase domain + inhibitor<br /> | ||
| + | **[[6fnf]], [[6fng]], [[6fnh]] – hEPHR A2 kinase domain + pyrimidine derivative<br /> | ||
**[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | **[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | ||
| Line 60: | Line 69: | ||
**[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | **[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | ||
**[[2lw8]] - hEPHR A4 LBD – NMR<br /> | **[[2lw8]] - hEPHR A4 LBD – NMR<br /> | ||
| + | **[[6fnl]] – hEPHR A4 kinase domain<br /> | ||
**[[2hel]] – mEPHR A4 membrane and kinase domains – mouse<br /> | **[[2hel]] – mEPHR A4 membrane and kinase domains – mouse<br /> | ||
**[[2y6m]] – mEPHR A4 kinase domain<br /> | **[[2y6m]] – mEPHR A4 kinase domain<br /> | ||
| Line 70: | Line 80: | ||
**[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | **[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | ||
**[[4bkf]] - hEPHR A4 ectodomain + ephrin B3 LBD<br /> | **[[4bkf]] - hEPHR A4 ectodomain + ephrin B3 LBD<br /> | ||
| + | **[[6fnm]] – hEPHR A4 kinase domain + dasatinib<br /> | ||
| + | **[[6fni]], [[6fnj]], [[6fnk]] – hEPHR A4 kinase domain + pyrimidine derivative<br /> | ||
**[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | **[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | ||
**[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | **[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | ||
| Line 76: | Line 88: | ||
**[[2r2p]] - hEPHR A5 kinase domain<BR /> | **[[2r2p]] - hEPHR A5 kinase domain<BR /> | ||
| + | **[[4et7]] – hEPHR A5 LBD (mutant)<br /> | ||
**[[1shx]] - mEPHR A5 <br /> | **[[1shx]] - mEPHR A5 <br /> | ||
| - | **[[ | + | **[[5zrz]] – mEPHR SAM domain + SAMD5<br /> |
| + | |||
*Ephrin A7 receptor | *Ephrin A7 receptor | ||
| + | |||
**[[3nru]] – hEPHR A7 LBD<BR /> | **[[3nru]] – hEPHR A7 LBD<BR /> | ||
**[[3h8m]] – hEPHR A7 SAM<BR /> | **[[3h8m]] – hEPHR A7 SAM<BR /> | ||
Revision as of 07:42, 23 June 2019
| |||||||||||
3D Structures of ephrin receptors
Updated on 23-June-2019
References
- ↑ Pitulescu ME, Adams RH. Eph/ephrin molecules--a hub for signaling and endocytosis. Genes Dev. 2010 Nov 15;24(22):2480-92. doi: 10.1101/gad.1973910. PMID:21078817 doi:http://dx.doi.org/10.1101/gad.1973910
- ↑ Genander M, Frisen J. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol. 2010 Oct;22(5):611-6. doi: 10.1016/j.ceb.2010.08.005. PMID:20810264 doi:http://dx.doi.org/10.1016/j.ceb.2010.08.005
- ↑ Davis TL, Walker JR, Allali-Hassani A, Parker SA, Turk BE, Dhe-Paganon S. Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 2009 Aug;276(16):4395-404. PMID:19678838 doi:http://dx.doi.org/10.1111/j.1742-4658.2009.07147.x
